title: Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis.
abstract: High-affinity folate receptors (FRs) are expressed at elevated levels on many human tumors. Bispecific antibodies that bind the FR and the T-cell receptor (TCR) mediate lysis of these tumor cells by cytotoxic T lymphocytes. In this report, conjugates that consist of folate covalently linked to anti-TCR antibodies are shown to be potent in mediating lysis of tumor cells that express either the alpha or beta isoform of the FR. Intact antibodies with an average of five folate per molecule exhibited high affinity for FR+ tumor cells but did not bind to FR- tumor cells. Lysis of FR+ cell lines could be detected at concentrations as low as 1 pM (approximately 0.1 ng/ml), which was 1/1000th the concentration required to detect binding to the FR+ cells. Various FR+ mouse tumor cell lines could be targeted with each of three different anti-TCR antibodies that were tested as conjugates. The antibodies included 1B2, a clonotypic antibody specific for the cytotoxic T cell clone 2C; KJ16, an anti-V beta 8 antibody; and 2C11, an anti-CD3 antibody. These antibodies differ in affinities by up to 100-fold, yet the cytolytic capabilities of the folate/antibody conjugates differed by no more than 10-fold. The reduced size (in comparison with bispecific antibodies) and high affinity of folate conjugates suggest that they may be useful as immunotherapeutic agents in targeting tumors that express folate receptors.
authors.affiliation: Department of Biochemistry, University of Illinois, Urbana 61801, USA.
authors.forename: D M
authors.initials: DM
authors.lastname: Kranz
authors.forename: T A
authors.initials: TA
authors.lastname: Patrick
authors.forename: K E
authors.initials: KE
authors.lastname: Brigle
authors.forename: M J
authors.initials: MJ
authors.lastname: Spinella
authors.forename: E J
authors.initials: EJ
authors.lastname: Roy
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002352:Carrier Proteins / Q000276:immunology* / Q000502:physiology; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D058973:Folate Receptors, GPI-Anchored; D005492:Folic Acid / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology*; D007700:Kinetics; D007939:Leukemia L1210 / Q000276:immunology; D007942:Leukemia, Experimental / Q000276:immunology; D051379:Mice; D008811:Mice, Inbred DBA; D011948:Receptors, Antigen, T-Cell / Q000276:immunology* / Q000502:physiology; D011956:Receptors, Cell Surface; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D058973:Folate Receptors, GPI-Anchored; D018796:Immunoconjugates; D011948:Receptors, Antigen, T-Cell; D011956:Receptors, Cell Surface; D005492:Folic Acid